Peptide-targeted radionuclide therapy for melanoma.
Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma. Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal tissues and organs. This review highlights the recent advances of peptide-targeted radionuclide therapy of melanoma targeting MC1-R and melanin. The promising therapeutic efficacies of 188Re-(Arg(11))CCMSH (188Re-[Cys(3,4,10), D-Phe(7),Arg(11)]-alpha-MSH(3-13)), 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[ReO-(Cys(3,4,10), D-Phe(7), Arg(11))]-alpha-MSH(3-13)) and 188Re-HYNIC-4B4 (188Re-hydrazinonicotinamide-Tyr-Glu-Arg-Lys-Phe-Trp-His-Gly-Arg-His) in preclinical melanoma-bearing models demonstrate an optimistic outlook for peptide-targeted radionuclide therapy for melanoma. Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease. The lack of effective treatments for metastatic melanoma and end-stage disease underscores the necessity to develop and implement new treatment strategies, such as peptide-targeted radionuclide therapy.
Miao
Yubin
Y
College of Pharmacy, University of New Mexico, 2502 Marble NE, MSC09 5360, Albuquerque, NM 87131, USA. ymiao@salud.unm.edu
Quinn
Thomas P
TP
D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D008543:Melanins / Q000627:therapeutic use; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging*; D051379:Mice; D010455:Peptides / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D044102:Receptor, Melanocortin, Type 1 / Q000378:metabolism; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D008543:Melanins; D010455:Peptides; D011868:Radioisotopes; D044102:Receptor, Melanocortin, Type 1